Details

Autor(en) / Beteiligte

• Bergmeijer, Thomas O
• Vos, Gerrit Ja
• Claassens, Daniël Mf
• Janssen, Paul Wa
• Harms, Remko
• der Heide, Richard van
• Asselbergs, Folkert W
• Ten Berg, Jurriën M
• Deneer, Vera Hm

Titel

Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy

Ist Teil von

• Pharmacogenomics, 2018-05, Vol.19 (7), p.621-628

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients). For both projects, the time to genotyping result was calculated. In the Popular Risk Score project (n = 2556), median time from blood collection to genotyping result was 4:04 h. In the Popular Genetics study (n = 1038), median time from randomization to genotyping result was 2:24 h. CYP2C19 genotyping is feasible in everyday clinical practice, both in the acute and non-acute settings.